在Miktoarm的基于聚合物的纳米配方上揭示溶解和再分散效应
Samaneh Yousefi Adlsadabad1, Gabriel Théberge-Julien2, Fatima Fernanda Portillo Gutierrez1
1Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, QC H3A 0B8, Canada.
International journal of molecular sciences
|October 29, 2025
概括
聚乙烯甘醇 (PEG2k) 1% w/v 是一种有效的冷保护剂,可以在冷干燥和复制过程中稳定星聚合物纳米颗粒,从而保持它们的特性和生物有效性.
科学领域:
- 聚合物化学 聚合物化学
- 纳米技术纳米技术
- 制药科学 制药科学
背景情况:
- 使用聚合物纳米颗粒的治疗干预需要稳定的配方来有效提供.
- 通过冷干燥将水性纳米粒子配方转化为干粉对于储存和处理至关重要.
- 了解冷保护剂在冷化过程中对纳米粒子稳定性的影响是必不可少的.
研究的目的:
- 研究冷保护剂在冷干燥和复制过程中对恒星聚合物纳米颗粒的物理化学和生物特性的影响.
- 确定最佳的冷保护剂条件,以保持纳米粒子完整性和药物有效性.
- 评估冷保护剂选择,分子量和度的作用.
主要方法:
- 基于聚合物的纳米粒子 miktoarm 的评估.
- 纳米颗粒配方用各种冷保护剂 (PEG2k,PEG5k,葡萄糖,糖糖,三糖,曼尼醇) 的冷化.
- 评估纳米粒子完整性,药物释放动力学和生物疗效 (细胞毒性和抗炎作用).
主要成果:
- 1% w/v 的 PEG2k 显示出最佳的冷保护,在冷化和再分散后保留纳米粒子和黄素的特性.
- 在维护细胞完整性方面,PEG2k (1% w/v) 优于其他冷保护剂,如PEG5k和各种糖化物.
- 纳米配方保护内皮细胞免受黄素的细胞毒性影响,加加冷保护剂/化并没有影响抗炎疗效.
结论:
- 使用PEG2k (1% w/v) 的优化冷保护使得恒星聚合物纳米颗粒的稳定,可再分散的干粉成为可能.
- 随着适当的冷保护,冷化和复制过程保留了纳米粒子配方的治疗潜力.
- 这种方法扩大了聚合物纳米粒子治疗应用的范围.
相关概念视频
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.6K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.6K
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
660
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
660
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
146
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
146